The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Understanding the results of MORPHO: gilteritinib as post-transplant maintenance for FLT3-ITD AML
Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, shares insights into the results of MORPHO (NCT02997202), a randomized trial of gilteritinib versus placebo as post-transplant maintenance for FLT3-ITD acute myeloid leukemia (AML) in first remission. Dr Levis highlights that the trial’s negative outcome could be attributed to the heterogeneity of the patient population, and notes that patients with measurable residual disease pre- or post-transplant were the ones who benefited from gilteritinib. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
